Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab

The use of checkpoint inhibitors has been associated with multiple ocular and orbital complications including Vogt-Koyanagi-Harada disease. In the current case, a 55-year-old man presented with visual changes 3 months following discontinuation of nivolumab for metastatic renal cell carcinoma. This i...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 54(2023), 3 vom: 15. März, Seite 183-187
1. Verfasser: Tieger, Marisa Gobuty (VerfasserIn)
Weitere Verfasser: Eliott, Dean, Cakir, Bertan, Dahrouj, Mohammad
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Case Reports Journal Article Nivolumab 31YO63LBSN Immune Checkpoint Inhibitors
LEADER 01000caa a22002652c 4500
001 NLM354493299
003 DE-627
005 20250304133854.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.3928/23258160-20230221-06  |2 doi 
028 5 2 |a pubmed25n1181.xml 
035 |a (DE-627)NLM354493299 
035 |a (NLM)36944065 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Tieger, Marisa Gobuty  |e verfasserin  |4 aut 
245 1 0 |a Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 17.08.2023 
500 |a Date Revised 17.08.2023 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a The use of checkpoint inhibitors has been associated with multiple ocular and orbital complications including Vogt-Koyanagi-Harada disease. In the current case, a 55-year-old man presented with visual changes 3 months following discontinuation of nivolumab for metastatic renal cell carcinoma. This is the second report of delayed presentation following discontinuation of a checkpoint inhibitor and the only case not associated with an alternative targeted therapy at the time of presentation. This article highlights a unique presentation of delayed checkpoint inhibitor-associated Vogt-Koyanagi-Harada and summarizes the reported cases. [Ophthalmic Surg Lasers Imaging Retina 2023;54(3):183-187.] 
650 4 |a Case Reports 
650 4 |a Journal Article 
650 7 |a Nivolumab  |2 NLM 
650 7 |a 31YO63LBSN  |2 NLM 
650 7 |a Immune Checkpoint Inhibitors  |2 NLM 
700 1 |a Eliott, Dean  |e verfasserin  |4 aut 
700 1 |a Cakir, Bertan  |e verfasserin  |4 aut 
700 1 |a Dahrouj, Mohammad  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Ophthalmic surgery, lasers & imaging retina  |d 2013  |g 54(2023), 3 vom: 15. März, Seite 183-187  |w (DE-627)NLM224956647  |x 2325-8179  |7 nnas 
773 1 8 |g volume:54  |g year:2023  |g number:3  |g day:15  |g month:03  |g pages:183-187 
856 4 0 |u http://dx.doi.org/10.3928/23258160-20230221-06  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_40 
912 |a GBV_ILN_63 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_90 
912 |a GBV_ILN_91 
912 |a GBV_ILN_130 
912 |a GBV_ILN_135 
912 |a GBV_ILN_136 
912 |a GBV_ILN_151 
912 |a GBV_ILN_181 
912 |a GBV_ILN_203 
912 |a GBV_ILN_217 
912 |a GBV_ILN_235 
912 |a GBV_ILN_289 
912 |a GBV_ILN_294 
912 |a GBV_ILN_297 
912 |a GBV_ILN_350 
912 |a GBV_ILN_352 
912 |a GBV_ILN_674 
912 |a GBV_ILN_676 
912 |a GBV_ILN_688 
912 |a GBV_ILN_698 
912 |a GBV_ILN_721 
912 |a GBV_ILN_737 
912 |a GBV_ILN_791 
912 |a GBV_ILN_812 
912 |a GBV_ILN_1127 
951 |a AR 
952 |d 54  |j 2023  |e 3  |b 15  |c 03  |h 183-187